Cargando…

HCV Kinetic Models and Their Implications in Drug Development

Chronic infection with hepatitis C virus (HCV) affects about 170 million people worldwide and is a major cause of liver complications. Mathematical modeling of viral kinetics under treatment has provided insight into the viral life cycle, treatment effectiveness, and drugs' mechanisms of action...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, THT, Guedj, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429577/ https://www.ncbi.nlm.nih.gov/pubmed/26225247 http://dx.doi.org/10.1002/psp4.28

Ejemplares similares

HCV Glycoprotein Structure and Implications for B-Cell Vaccine Development
por: Ströh, Luisa J., et al.
Publicado: (2020)

HCV and Oxidative Stress: Implications for HCV Life Cycle and HCV-Associated Pathogenesis
por: Medvedev, Regina, et al.
Publicado: (2016)

Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases
por: Flego, Michela, et al.
Publicado: (2013)

Targeting HCV Entry For Development of Therapeutics
por: Wong-Staal, Flossie, et al.
Publicado: (2010)

HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients
por: Canini, Laetitia, et al.
Publicado: (2017)

Virologic Tools for HCV Drug Resistance Testing
por: Fourati, Slim, et al.
Publicado: (2015)

HCV Subtype Characterization among Injection Drug Users: Implication for a Crucial Role of Zhenjiang in HCV Transmission in China
por: Zhang, Chiyu, et al.
Publicado: (2011)

Are improper kinetic models hampering drug development?
por: Walsh, Ryan
Publicado: (2014)

Multi-scale modeling of drug binding kinetics to predict drug efficacy
por: Clarelli, Fabrizio, et al.
Publicado: (2019)

HCV and drug addiction in the historical scenario of infection entry in Italy
por: Massimo, Galli, et al.
Publicado: (2018)

Mathematical Modeling of Bacterial Kinetics to Predict the Impact of Antibiotic Colonic Exposure and Treatment Duration on the Amount of Resistant Enterobacteria Excreted
por: Nguyen, Thu Thuy, et al.
Publicado: (2014)

Hepatitis C Virus (HCV) Genotype 1 Subtype Identification in New HCV Drug Development and Future Clinical Practice
por: Chevaliez, Stéphane, et al.
Publicado: (2009)

Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users
por: Flynn, Jacqueline K, et al.
Publicado: (2014)

Population Health and Cost-Effectiveness Implications of a “Treat All” Recommendation for HCV: A Review of the Model-Based Evidence
por: Cipriano, Lauren E., et al.
Publicado: (2018)

LncRNAs in HCV Infection and HCV-Related Liver Disease
por: Unfried, Juan P., et al.
Publicado: (2020)

Finally sofosbuvir: an oral anti-HCV drug with wide performance capability
por: Kayali, Zeid, et al.
Publicado: (2014)

Mapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development
por: Cuypers, Lize, et al.
Publicado: (2016)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

Implications of hcv natural genetic diversity on HCV NS5B inhibitor NM283
por: Demetriou, Victoria L, et al.
Publicado: (2010)

Analysis of drug combinations: current methodological landscape
por: Foucquier, Julie, et al.
Publicado: (2015)

The endocannabinoid system – current implications for drug development
por: Fowler, C. J.
Publicado: (2021)

Phylodynamic Analysis and Implication of HCV Genotype 4 Variability on Antiviral Drug Response and T-Cell Recognition
por: Colomba, Giuseppina Maria Elena, et al.
Publicado: (2020)

Hepatitis C virus (HCV) infection and re-infection among HCV- and HIV/HCV-infected injection drug users
por: Conway, B, et al.
Publicado: (2010)

Kinetics of miR-122 Expression in the Liver during Acute HCV Infection
por: Choi, Youkyung, et al.
Publicado: (2013)

HCV Spread Kinetics Reveal Varying Contributions of Transmission Modes to Infection Dynamics
por: Durso-Cain, Karina, et al.
Publicado: (2021)

Developments in the HCV Screening Technologies Based on the Detection of Antigens and Antibodies
por: Warkad, Shrikant Dashrath, et al.
Publicado: (2019)

HCV-Specific T Cell Responses During and After Chronic HCV Infection
por: Luxenburger, Hendrik, et al.
Publicado: (2018)

HCV core antigen plays an important role in the fight against HCV as an alternative to HCV‐RNA detection
por: Wang, Yuhan, et al.
Publicado: (2021)

New anti HCV drugs in the pipeline
por: Bourlière, Marc
Publicado: (2010)

New drug interactions in HIV and HCV
por: Back, David
Publicado: (2012)

Regulation of gene expression by microRNA in HCV infection and HCV–mediated hepatocellular carcinoma
por: Gupta, Priyanka, et al.
Publicado: (2014)

HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection: implications for improved diagnostic option in an era of affordable DAAs
por: Wasitthankasem, Rujipat, et al.
Publicado: (2017)

Mathematical Modeling of Release Kinetics from Supramolecular Drug Delivery Systems
por: Mircioiu, Constantin, et al.
Publicado: (2019)

HCV and Lymphoproliferation
por: Zignego, Anna Linda, et al.
Publicado: (2012)

Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications
por: Kaur, Kirpal, et al.
Publicado: (2015)

Comparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit drug users
por: Jamalidoust, Marzieh, et al.
Publicado: (2017)

HBV and HCV Therapy
por: Lampertico, Pietro, et al.
Publicado: (2009)

HCV and immigration in Italy
por: Massimo, Galli, et al.
Publicado: (2018)

Animal Models of Inflammation for Screening of Anti-inflammatory Drugs: Implications for the Discovery and Development of Phytopharmaceuticals
por: Patil, Kalpesh R., et al.
Publicado: (2019)

Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens
por: Cento, Valeria, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4in7kviv6eri7de9lt48kktbc1